FVB.Cg-Tg(IghMyc)186Brn/Cnrm
| Status | Available to order |
| EMMA ID | EM:00412 |
| Citation information | RRID:IMSR_EM:00412 Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information. |
| International strain name | FVB.Cg-Tg(IghMyc)186Brn/Cnrm |
| Alternative name | Emyc |
| Strain type | Transgenic Strains |
| Allele/Transgene symbol | Tg(IghMyc)186Brn |
| Gene/Transgene symbol | Tg(IghMyc)186Brn |
Information from provider
| Provider | Anton Berns |
| Provider affiliation | Research - Animal Facility, The Netherlands Cancer Institute |
| Genetic information | Zygote injection of transgene: c-myc (myelocytomatosis oncogene) cDNA under control of the lymphoid-specific immunoglobulin heavy chain enhancer (E-mu). |
| Phenotypic information | Predisposition to B cell lymphomagenesis, latency 3-12 months. Due to the early onset, mice should be kept as heterozygotes. |
| Breeding history | The transgene was injected into B6CBA F2 zygotes and was maintained on either B6CBA F1 and/or FVB/N for several years. Mice are now maintained on FVB/N for at least N=3. |
| References |
|
Information from EMMA
| Archiving centre | CNR, Consiglio Nazionale delle Ricerche, Monterotondo, Italy |
Literature references
- Mice bearing the E mu-myc and E mu-pim-1 transgenes develop pre-B-cell leukemia prenatally.;Verbeek S, van Lohuizen M, van der Valk M, Domen J, Kraal G, Berns A, ;1991;Molecular and cellular biology;11;1176-9; 1990273